Skip to main content

Advertisement

Table 1 Summary of interventions, study details, results and quality of evidence

From: Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy

Source N (Intervention: Placebo) Study Type PI-IBS inclusion criteria Intervention (Type, dose, length of intervention, frequency) Duration of intervention Outcome(s) Quality of evidence (modified GRADE [17])
Bafutto et al., 2011 61 (18:43) cohort Rome III with IBS-D, as reported by patient - Mesalazine 30 days - stool frequency decreased by 1.33 stools/day on average Moderate
- 30 days The study is unclear as to how the randomization and allocation concealment were conducted.
- 800 mg
- TID
- stool form and consistency improved by 2.17 based on the Bristol stool scale (16)
Hanevik et al., 2011 18 (11:7) RCT History of giardiasis 2 years prior and Rome II criteria - Mesalazine 6 weeks - no significant change in symptoms following mesalazine treatment Low
- 6 weeks The study was a pilot study with small sample. It is unclear as to how to randomization and allocation concealment were conducted
- 800 mg
- BID
Tuteja et al., 2012 20 (10:10) RCT Onset of IBS symptoms in previously asymptomatic individuals after acute gastroenteritis characterized by two or more of: diarrhea, vomiting, fever, as reported by the patient - Mesalamine 12 weeks - no significant change in symptoms following mesalazine treatment Low
- 12 weeks Insufficient sample size
- 1.6 g
- BID
Dizdar et al., 2007 34 (15:39) RCT Persisting abdominal symptoms 12 months after Giardia infection and Rome II criteria, as reported by Giardia outpatient clinic - Ondansetron 2 days - no significant improvement in symptoms after ondansetron treatment - Significant improvement in post-prandial nausea score before vs after ondanestron treatment (27.47 ± 21.89 vs 41.40 ± 23.04) Moderate
- 2 days Small sample size
- 8 mg
- QD
Dunlop et al., 2003 34 (20:14) RCT New bowel symptoms in a previously asymptomatic individuals immediately after an acute illness characterized by two or more of: diarrhea, fever, vomiting, positive stool culture, as recorded by the patient or gastroenterology clinic - Prednisone 21 days - No improvement in abdominal pain, diarrhea, frequency or urgency based on a gastrointestinal symptom rating scale Moderate
- 21 days Small sample size
- 30 mg
- QD
Menon et al., 2011 25 (15:10) Retrospective History of an acute gastroenteritis precipitating chronic diarrhea, as reported in clinic notes and hospital database - Cholestyramine Variable (1–15 years) - decrease in diarrhea frequency of 5.9 stools/day Low
- 1–15 years Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.
- 8.22 g
- QD
Niaz et al., 1997 16 (16:0) Retrospective History of an acute gastroenteritis precipitating chronic diarrhea defined as distinct change in bowel habit with 4–15 loose watery motions per day as reported by the patient - Cholestyramine 2 weeks - decreased stool frequency of 5.1 stools/day Low
- 2 weeks Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.
- 2–16 g
- QD
Thakur et al., 2009 76 (17:59) RCT Rome II criteria and history of gastroenteritis or dysentery as reported by the patient -Metronidazole 7 days - improvement in pain, stool and total symptom scores at days 7 and 28 Low
Study was not randomized, and both patient and physician were not blinded. 9 patients were lost to follow-up but it is unclear if they were included in analysis.
- 4 weeks
- 400 mg
- TID
- stool symptoms continued to improve between day 7 and 28 even though patients were no longer taking the medication
Lifshitz et al., 1990 29 (10:19) RCT History of chronic diarrhea after an episode of gastroenteritis lasting more than 3 weeks as reported by Pediatric Gastroenterology unit - Pregestimil variable - 9 out of 10 infants had improved clinical symptoms, shorter time to improvement Moderate
- 3 – 7 days Population was limited to infants with lactose intolerance. Inclusion was based on chronic diarrhea, not on established criteria such as Rome criteria.
- 1500 mL/kg
- Daily to provide 70 kcal/kg